Dr. Campbell is a graduate of Morehouse College and Case Western Reserve School of Medicine. He completed his pediatric residency training at the Harvard-affiliated Massachusetts General Hospital; this was followed by a Pediatric Hematology/Oncology Fellowship at Northwestern University - Lurie’s Children’s Hospital. Currently, he is the Director of the Comprehensive Sickle Cell Disease (SCD) Program at Children’s National Hospital (CNH) in Washington, DC, one of the largest SCD programs in the country. He has been a leader in CNH’s approaches to workforce diversity, health equity, and inclusion. Dr. Campbell is an Associate Professor of Pediatrics at George Washington University, Washington, DC, and a Faculty Affiliate at the George Mason University, Manassas, Virginia. Prior to his role at CNH, he directed the University of Michigan Comprehensive Pediatric Hemoglobinopathies Program and Co-Directed the University of Michigan Minority Health International Research Training Program. His national work is ongoing as well. As an international expert, he has lectured regionally, nationally, and globally on issues related to the care and healthcare system approach to patients and families dealing with the effects of SCD. He has participated in numerous advocacy efforts for SCD patients and their families, which included assisting with sickle cell disease legislation (the Sickle Cell Disease Treatment Centers Act of 2022 and the Sickle Cell Care Expansion Act of 2022), presenting at the 2018 Congressional Briefing (US Capitol) on Sickle Cell Disease Funding, and presenting at a White House Sickle Cell Awareness meeting.
Dr. Campbell is currently the Principal Investigator of the American Society of Hematology Research Collaborative, “Washington DC, Maryland, Virginia Sickle Cell Clinical Trials Network”. For the past several years his research focused on the clinical complexity of sickle cell disease in different populations through a multinational international consortium (CASiRe - Consortium for the Advancement of Sickle Cell Disease Research), which he directs and includes participants from Ghana, Italy, United Kingdom, and the United States. Other international work includes being a member of the Sickle in Africa Research Consortia, where he serves as a contributor to the SCD Ontology Working Group.